There is evidence that the PERK UPR pathway is selectively activated in advanced PCa, resulting in elevated P-eIF2α, and changes in protein synthesis that promote aggressive tumor development, and this provides a biomarker for poor patient survival [14]. This evidence concerns the gene EIF2A and neoplasm.